The results were expressed as hazard ratios and the corresponding 95% CIs. In addition to the relative mortality between PI3K phosphorylation the 2 FITs, the absolute mortality reduction for each FIT was estimated and compared with nonparticipants with the adjustment of self-selection bias.14 The following equation was applied: RRadjustedforself-selectionbias=Screeningrate(SR)×RRparticipants/uninvited+(1-SR)×RRnon-participants/uninvited The calculation is detailed

in Supplementary Tables 2–4. Because the stage and location of screen-detected and interval cancers are of clinical significance,15 a subsidiary analysis was performed and a comparison was made between the 2 tests using the χ2 test. Cancer was staged according to the American Joint Committee on Cancer 7th staging system.16 The colon above the level of the splenic flexure (including the splenic flexure) was defined as the proximal colon. When concurrent proximal and distal cancers were present, subjects were placed into the distal colon category. All statistical analyses were performed using SAS version 9.2 (SAS Institute, Cary, NC). All P values were 2-sided and P < .05 was considered to indicate statistical significance. Between January 1, 2004 and December 31, 2009, Panobinostat clinical trial a total of 956,005 subjects underwent screening. Among them, 747,076 (78%) and

208,929 (22%) received the OC-Sensor and HM-Jack tests, respectively; their baseline data according to demographic characteristics, geography, and temperature, and characteristics of the confirmatory diagnosis are presented in Table 1. Small differences, which were statistically significant owing to the large sample size, were observed with respect to sex, follow-up time, confirmatory examination tool, colonoscopy adenoma detection rate, and colonoscopy advanced adenoma detection rate. Differences were more prominent in the geographic areas and the hospital levels where Tenoxicam confirmatory diagnoses were performed. As shown in Table 2, positivity rates were similar between the 2 tests (3.8% vs 3.9%), but the confirmatory examination rate was higher for those who received

HM-Jack (80.9% vs 85.3%). As expected, positivity rates were higher for males and those of older age as compared with the total population group. These findings were unchanged regardless of adjustments for sex and age distributions (data not shown). The effect of ambient temperature on FIT positivity was also evaluated. For the temperature ranges of 10–14°C, 15–19°C, 20–24°C, and ≥25°C, the positivity rates for OC-Sensor were 5.6%, 4.4%, 3.9%, and 3.6%, respectively, and for HM-Jack were 5.5%, 3.8%, 4.7%, and 3.6%, respectively, revealing an inverse association (P < .001) between FIT positivity and ambient temperature. The OC-Sensor test detected CRC in 0.21% of patients, with a positive predictive value of 6.8%.